These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 8203791)

  • 1. Safety and security of Daflon 500 mg in venous insufficiency and in hemorrhoidal disease.
    Meyer OC
    Angiology; 1994 Jun; 45(6 Pt 2):579-84. PubMed ID: 8203791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. At the Crossroads of Venous Insufficiency and Hemorrhoidal Disease: Daflon 500 mg. Proceedings of a symposium. Vienna, Austria, January 31, 1992.
    Angiology; 1994 Jun; 45(6 Pt 2):493-584. PubMed ID: 7911285
    [No Abstract]   [Full Text] [Related]  

  • 3. Advantage of a micronized flavonoidic fraction (Daflon 500 mg) in comparison with a nonmicronized diosmin.
    Amato C
    Angiology; 1994 Jun; 45(6 Pt 2):531-6. PubMed ID: 8203783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlled studies of Daflon 500 mg in chronic venous insufficiency.
    Geroulakos G; Nicolaides AN
    Angiology; 1994 Jun; 45(6 Pt 2):549-53. PubMed ID: 8203786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind, placebo-controlled evaluation of clinical activity and safety of Daflon 500 mg in the treatment of acute hemorrhoids.
    Cospite M
    Angiology; 1994 Jun; 45(6 Pt 2):566-73. PubMed ID: 8203789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The drug therapy of chronic venous insufficiency (a trial of the clinical use of the preparation Detralex)].
    Iablokov EG; Bogachev VIu; Domoradskaia AI
    Ter Arkh; 1996; 68(10):80-1. PubMed ID: 9026954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flavonoids. A review of the pharmacology and therapeutic efficacy of Daflon 500 mg in patients with chronic venous insufficiency and related disorders.
    Struckmann JR; Nicolaides AN
    Angiology; 1994 Jun; 45(6):419-28. PubMed ID: 8203767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is There a Difference in the Clinical Efficacy of Diosmin and Micronized Purified Flavonoid Fraction for the Treatment of Chronic Venous Disorders? Review of Available Evidence.
    Cazaubon M; Benigni JP; Steinbruch M; Jabbour V; Gouhier-Kodas C
    Vasc Health Risk Manag; 2021; 17():591-600. PubMed ID: 34556990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laser Doppler and transcutaneous oximetry: modern investigations to assess drug efficacy in chronic venous insufficiency.
    Belcaro G; Cesarone MR; de Sanctis MT; Incandela L; Laurora G; Février B; Wargon C; De Gregoris P
    Int J Microcirc Clin Exp; 1995; 15 Suppl 1():45-9. PubMed ID: 8748889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Micronised purified flavonoid fraction: a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids.
    Lyseng-Williamson KA; Perry CM
    Drugs; 2003; 63(1):71-100. PubMed ID: 12487623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapeutic potential of micronized purified flavonoid fraction (MPFF) of diosmin and hesperidin in treatment chronic venous disorder].
    Hnátek L
    Vnitr Lek; 2015 Sep; 61(9):807-14. PubMed ID: 26465280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapeutic effectiveness of flavonoids illustrated by daflon 500 mg].
    Hitzenberger G
    Wien Med Wochenschr; 1997; 147(18):409-12. PubMed ID: 9454438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An original microhaemorheological approach to the pharmacological effects of Daflon 500 mg in severe chronic venous insufficiency.
    Allegra C; Bartolo M; Carioti B; Cassiani D
    Int J Microcirc Clin Exp; 1995; 15 Suppl 1():50-4. PubMed ID: 8748890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daflon 500 mg in the treatment of hemorrhoidal disease: a demonstrated efficacy in comparison with placebo.
    Godeberge P
    Angiology; 1994 Jun; 45(6 Pt 2):574-8. PubMed ID: 8203790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A long term treatment with a venotropic drug. Results on efficacy and safety of Daflon 500 mg in chronic venous insufficiency.
    Guillot B; Guilhou JJ; de Champvallins M; Mallet C; Moccatti D; Pointel JP
    Int Angiol; 1989; 8(4 Suppl):67-71. PubMed ID: 2632651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective randomized controlled trial of a micronized flavonidic fraction to reduce bleeding after haemorrhoidectomy.
    Ho YH; Foo CL; Seow-Choen F; Goh HS
    Br J Surg; 1995 Aug; 82(8):1034-5. PubMed ID: 7648143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. At the crossroads of venous insufficiency and hemorrhoidal disease: Daflon 500 mg--repercussions of venous insufficiency on everyday life.
    Launois R
    Angiology; 1994 Jun; 45(6 Pt 2):495-504. PubMed ID: 8203779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hemorrhoids and conservative treatment. Review of the literature on the use of diosmin and micronized hesperidin].
    La Torre F; Nicolai AP; Otti M
    Minerva Chir; 1999 Dec; 54(12):909-16. PubMed ID: 10736998
    [No Abstract]   [Full Text] [Related]  

  • 19. Are the phlebotonic properties shown in clinical pharmacology predictive of a therapeutic benefit in chronic venous insufficiency? Our experience with Daflon 500 mg.
    Tsouderos Y
    Int Angiol; 1989; 8(4 Suppl):53-9. PubMed ID: 2698902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Daflon 500 mg in venous leg ulcer healing: a double-blind, randomized, controlled versus placebo trial in 107 patients.
    Guilhou JJ; Dereure O; Marzin L; Ouvry P; Zuccarelli F; Debure C; Van Landuyt H; Gillet-Terver MN; Guillot B; Levesque H; Mignot J; Pillion G; Février B; Dubeaux D
    Angiology; 1997 Jan; 48(1):77-85. PubMed ID: 8995348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.